877PFirst-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial. (23rd October 2018) - Vaishampayan, U N; Schöffski, P; Ravaud, A; Borel, C; Song, T; Guenther, S; Grewal, J; Gulley, J